BioSpace News Archive

BPN14770, which is being developed by Tetra Discovery Partners for the treatment of fragile X syndrome (FXS), was granted Orphan Drug Designation by the FDA in April 2018.

Gordon Thomas Honeywell Governmental Affairs (GTH-GA) has announced that the Melanie Road murder case investigated by the Avon Somerset Constabulary (United Kingdom) was selected as the 2018 DNA Hit of the Year.

IntechOpen announced the selected books for the “IntechOpen Women in Sciences 2018” Book Collection.

Innovus Pharmaceuticals, Inc. announced that the Company will release its March 31, 2018 first quarter financial results on Monday, May 14, 2018.

Varian commented on the press release of Sirtex Medical Limited (Sirtex) dated May 4, 2018

St. Mary’s General Hospital Foundation hosts RedDAY to raise awareness of the serious risk of heart disease in women.

ImmunoGen, Inc. reviewed recent progress in the business and reported operating results for the quarter ended March 31, 2018.

Total revenues increased by 25%, driven by SPINRAZA royalties More than $2 billion of cash expected upon closing of Biogen transaction Expanded strategic neurology research collaboration with Biogen and invested in TEGSEDI™ commercialization through Akcea Conference call and webcast today, May 4, 2018, at 11:30 a.m. Eastern Time

Alkermes plc announced a new competitive awards program, the ALKERMES Pathways Research AwardsSM Program.

CStone Pharmaceuticals (Suzhou) Co., Ltd., (CStone) today announced dosing of the first patient of a Phase I clinical trial in Australia for CS1002, an investigational drug targeting cytotoxic T-lymphocyte-associated protein-4 (CTLA-4). CS1002 is CStone’s first drug candidate that has entered clinical trials outside of China.